RCT | Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease.

Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial – The Lancet Gastroenterology & Hepatology (free registration required)

Commentary: Etrolizumab Increases Chance of Clinical Remission for Crohn’s Disease – HCP Live

Commentary on Twitter

New research – Sandborn et al – Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial https://t.co/I81bEfz5WU#IBD #GITwitter #UEGWeek pic.twitter.com/lwnl1EI7cz

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) October 12, 2022